Foundayo vs Zepbound: Compare the Pill and the Shot
A daily tablet and a weekly injection, both from Lilly. What actually changes day to day - and how to track whichever one your doctor picks.
Quick answer
Foundayo and Zepbound are both Eli Lilly medications for chronic weight management, and the practical difference is the routine. Foundayo (orforglipron) is a once-daily pill with no food or water rules, approved by the FDA in April 2026. Zepbound (tirzepatide) is a once-weekly shot, approved for weight management and also for obstructive sleep apnea. They were tested in separate trials, not against each other: 12.4% average weight loss at Foundayo's highest dose among people who stayed on treatment over 72 weeks in ATTAIN-1, and 20.9% at the highest Zepbound dose over 72 weeks in SURMOUNT-1 - direction, not a guarantee for any one person. The choice belongs with you and your doctor. MeAgain tracks either one - daily pill habit or weekly shot day - and 421K people already use it, rated 4.8 stars across 21K App Store ratings.
Bottom line: This page is education, not medical advice. Medication choice and dose changes belong with your doctor or licensed clinician. MeAgain works with any GLP-1, branded or compounded, wherever it is prescribed.
The Pill-vs-Shot Differences at a Glance
The differences that show up in real life, from the FDA labels - not a verdict on which medication is better. That question belongs to you and your doctor.
| Day-to-day question | Foundayo | Zepbound |
|---|---|---|
| How it's taken | Pill, once daily | Shot, once weekly |
| Food and water rules | None - any time, with or without food | None on timing; rotate injection sites each dose |
| Storage | Room temperature, no fridge | Fridge until in use; up to 21 days at room temp once in use |
| Missed dose | Skip it; resume next day - never double up | Take within 4 days; after that, skip to the next weekly dose |
| How it works | One hunger signal (GLP-1), non-peptide pill | Two hunger signals (GLP-1 + GIP) |
| Also approved for | Weight management only (as of July 2026) | Obstructive sleep apnea in adults with obesity (Dec 2024) |
| Travel | Pill bottle in a bag | Cooler or fridge access for unopened pens |
What MeAgain does not do: No medical advice, no diagnosis, no treatment, no insurance billing. MeAgain is a tracking and education app, not a clinical service — clinical decisions stay with your licensed clinician.
Key takeaways
The lived difference is rhythm: Foundayo is a pill every day - any time, with or without food - while Zepbound is a shot once a week with rotating injection sites. Neither routine is harder to track; they are just different habits.
Approvals are not identical. Zepbound is FDA-approved for weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Foundayo is approved for weight management only - it is not approved for type 2 diabetes as of July 2026.
The weight-loss numbers you see quoted for these two came from separate trials that never ran head-to-head, so published averages point a direction at best. The full figures and their caveats live further down this page - your own weekly log is what makes them personal.
MeAgain's medication graph adapts to either rhythm: a daily curve for the pill (about a 24-hour half-life) or a weekly rise-and-fade for the shot (about 5 days). Reminders carry the pill habit; the shot-day countdown carries the week.
If you and your doctor ever switch between them, your history comes along: weight trend, meals, symptoms, and dose dates stay on one timeline. 421K users track their GLP-1 with MeAgain, rated 4.8 stars across 21K ratings.
Tracking a Daily Pill vs Tracking a Weekly Shot
01The Daily Pill Habit, Held Up by Reminders
Foundayo removes the rules that made older GLP-1 pills fussy - no empty stomach, no water limit, any time of day - but that flexibility cuts both ways: with no fixed ritual, a dose is easier to forget. MeAgain gives the pill a rhythm: a daily reminder at the time you choose, a one-tap log, and a dose heatmap that shows the month at a glance, gaps and all. Miss a day? The label says skip it and take the next dose on schedule - never double up - and the log keeps that honest, so you are not standing in the kitchen trying to remember whether yesterday happened. Dose steps matter too: each Foundayo step lasts at least 30 days, and the app keeps the start date of your current step visible. A daily medication lives or dies on streaks, and streaks are exactly what a tracker is for.
02Shot Day, Sites, and the Space Between
Zepbound runs on a weekly clock. MeAgain keeps the countdown to your next shot visible, logs the dose and the injection site, and rotates you to a different site automatically next time - abdomen, thigh, or upper arm, per the label. Between shots, the medication graph shows the rise, peak, and fade across the week, which is often when appetite and side effects finally make sense: day two can feel different from day six because the level is different, and seeing that on a chart beats guessing. The log also carries the practical details a weekly routine collects - which pen dose you are on, when the step started, what the label says about a missed week. One shot a week sounds simple; the tracker is for the six days in between.
03Side Effects: Same Core List, Same 0-10 Log
The honest comparison on side effects is that the core list overlaps heavily - nausea, constipation, diarrhea, vomiting, stomach pain, fatigue - because both medications quiet appetite through the same family of signals. Foundayo's label also lists burping, heartburn, and hair loss; Zepbound adds injection-site reactions, which a pill cannot have. MeAgain logs all of it the same way: the 18 most common GLP-1 side effects plus unlimited custom symptoms, each on a 0-10 scale with timestamps. After a few weeks, you are not comparing brochures - you are reading your own pattern next to your own doses.
04Switch Between Them Without Losing Your Story
Plenty of people will try one and move to the other - insurance changes, side effects, preference for a pill over a needle, or the reverse. In MeAgain, a switch is a settings change, not a fresh start: your weight trend, food logs, symptom history, and every past dose stay on one timeline, and the medication graph swaps from a daily curve to a weekly one (or back). The most useful comparison of Foundayo and Zepbound is not on this page - it is what your own body did in the months before and after a switch, and that only exists if the history is in one place.
Foundayo vs Zepbound: What Actually Changes Day to Day
What Each Medication Is
Foundayo is the brand name for orforglipron, the first daily GLP-1 pill designed without food or water restrictions. It is a different kind of molecule than the injectables - a small-molecule, non-peptide GLP-1 - which is why it survives the stomach without special rules. The FDA approved it for chronic weight management on April 1, 2026, with a dose ladder that steps up gradually: 0.8 mg to start, rising over months to a 17.2 mg maximum, each step at least 30 days.
Zepbound is the brand name for tirzepatide, a once-weekly injection that works on two appetite signals, GLP-1 and GIP. It was approved for weight management in November 2023 and for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024. Its ladder runs 2.5 mg (a starter month, not a treatment dose) up to 15 mg, each step at least 4 weeks. The same molecule is sold as Mounjaro for type 2 diabetes - Foundayo has no diabetes approval as of July 2026.
Both labels carry the same serious class warning about thyroid C-cell tumors seen in rodent studies, and neither is for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Both step up gradually for the same reason: stomachs need time to adjust.
About Those Weight-Loss Numbers
In ATTAIN-1, 3,127 adults took Foundayo or placebo for 72 weeks; people on the highest dose who stayed on treatment lost an average of 12.4% of body weight, and 59.6% of them lost at least 10%. In SURMOUNT-1, 2,539 adults took Zepbound or placebo for 72 weeks; the top dose averaged 20.9%. Those are different trials with different people - not a head-to-head - so they are direction, not destiny.
Averages also hide the part that matters for you: some people respond strongly to the pill, some tolerate the shot better, and side effects, insurance, and needle comfort all weigh in. That is why the honest version of this page ends in a log, not a verdict: track the medication you and your doctor pick, and let your own trend do the comparing.
Whichever way the choice goes - the daily pill, the weekly shot, or a switch between them later - the tracker works from day one and keeps the whole story on one timeline. MeAgain works with any GLP-1, branded or compounded, wherever it is prescribed.
This content is for informational purposes only and does not constitute medical advice. Medication choice, dose changes, and side-effect management belong with your doctor or licensed clinician. Foundayo and Zepbound are Eli Lilly medications.
Sources
- Foundayo (orforglipron) Prescribing Information (Eli Lilly)
- Zepbound (tirzepatide) Prescribing Information (Eli Lilly)
- FDA Novel Drug Approvals 2026 (Foundayo, April 1, 2026)
- FDA approval letter - Zepbound for obstructive sleep apnea (December 2024)
- Jastreboff AM et al. - Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, NEJM 2022, n=2,539)
- FDA approval letter - Foundayo (orforglipron), April 2026
What Zepbound and Pill Users Say About Tracking
One App for Both Sides of This Page
The medication decides the rhythm; the tracker carries it. One App Store reviewer (Ilanadrama, June 15, 2026) ran through her favorite features and landed on the weekly routine:
Plus keeping track of your shot and which side you do it on, and any symptoms you have is very helpful!
That is the pattern on either medication - the shot or the pill is one moment of the day or week, and the tracking around it (food, water, protein, symptoms, weight) is where the routine actually lives.
MeAgain was built for the whole GLP-1 category, not one brand: daily-pill reminders and dose heatmaps for Foundayo, shot-day countdowns and site rotation for Zepbound, and the same food, symptom, and weight tracking for both. If your prescription changes, the app changes with you - the history does not start over.
What Our Users Say
“I've been using the app for about 7 months now and I love how I'm able to track my meals and my daily medication. The little capybara widget is a great visual to help me know what my body needs.”
“This app does exactly what I needed with tracking shots… location, time, amount, current medication level, and reminders for the next one. That plus weight progress is all I needed, and after trying at least 5 others this was the only one that did it in a clean, logical way- and didn't cost a fortune!”
“I really love this app and how easy it is to use for my food, water, Mounjaro weekly shot and everything else. The app is totally worth the cost and it's been perfect for me.”
“I've been on my MJ journey since September 2025. Seeing my food intake has made a huge difference. Also, reviewing my shot locations has helped me remember to rotate. I have recommended this app to my friends who have also started their own journeys!”
“I love tracking water, protein and fiber on the app. It's really cool it's able to pull my weight and steps too. Add the widget to you phone screen if you do get it, I love that.”
Foundayo vs Zepbound - FAQs
No. They are different molecules from the same company, Eli Lilly. Foundayo is orforglipron, a once-daily pill that works on the GLP-1 signal only. Zepbound is tirzepatide, a once-weekly shot that works on two signals, GLP-1 and GIP. They share the family resemblance - appetite quiets, stomachs need an adjustment period, doses step up gradually - but the molecule, the route, and parts of the approval differ.
Your Journey Back to You,
One Day at a Time
Track the plan, dose, meals, and milestones in one place that actually keeps up with your day.